Introduction {#S1}
============

Tacrolimus (Tac), the primary immune suppressant used in \>90% of solid organ transplants[@R1], is a substrate of cytochrome P450 (CYP) enzymes CYP3A4 and CYP3A5. Tac has a narrow therapeutic window[@R2] with blood concentrations (troughs) that are highly associated with efficacy[@R3] and toxicity[@R4]. Tac troughs are routinely monitored to maintain a therapeutic range and guide dosing adjustments. Most African Americans (AAs) often have higher rates of Tac metabolism generally due to higher CYP3A5 expression. Consequently, AAs often require higher Tac doses than European Americans (EAs)[@R5]. High Tac clearance and low troughs in kidney transplant recipients during the first 90 days post-transplant is a risk factor for acute rejection[@R6].

There is large interpatient variability[@R7] in Tac metabolism which is partially due to genetic variants and clinical factors that alter clearance. Tac dosing equations including common genotypes for CYP3A single-nucleotide polymorphisms (SNPs) and clinical factors have been developed to personalize Tac dosing[@R8]^,^ [@R9]. However, dosing equations have not allowed for low-frequency variants (\<5% frequency in population) because few studies have been sufficiently powered to identify them. Thus, further understanding the genetics of Tac disposition, especially the low-frequency variants, could be translated into more precise Tac dosing strategies.

Genetic variants impact Tac troughs[@R10] by altering CYP3A4 and CYP3A5 enzyme expression, activity[@R11], transcription factors, co-enzymes or transporters. Previously, with a diverse cohort of kidney allograft recipients and a custom SNP array, we found that 52.5% of Tac trough variation in subjects was explained by a set of common SNPs and clinical variables[@R12]. Upon further investigation of Tac troughs using a genome-wide association study (GWAS), three loss-of-function (LoF) genetic variants, *CYP3A5\*3* (rs776746), *CYP3A5\*6* (rs10264272) and *CYP3A5\*7* (rs41303343), in AAs were highly associated with Tac troughs[@R7]; these three genetic variants and clinical factors, accounted for 53.9% of the Tac trough variability in AAs. In a cohort of EAs, *CYP3A5\*3* and*CYP3A4\*22* (rs35599367) were significantly associated with Tac troughs[@R13]. A limitation of GWAS SNP arrays is that the genotypes are typically restricted to known common genetic variants requiring alternative methods to identify low-frequency, and unknown, variants associated with Tac disposition.

We hypothesized that Tac trough variation between subjects is, in part, due to low-frequency genetic variants which may not be present on a GWAS SNP array. To identify low-frequency genetic variants associated with Tac metabolism, we used an extreme phenotype sampling (EPS) model and next generation sequencing (NGS). The EPS model allows increased statistical power with fewer specimens for analysis[@R14] and can account for known clinical factors and common genotypes[@R7]. Our EPS model investigated subjects with either the highest or lowest dose-normalized Tac troughs in our cohort. Because AAs often have different allele frequencies than EAs, we conducted a separate analysis for EAs and AAs. After selecting the subjects with extreme dose-normalized Tac troughs, and adjusting for clinical and common genetic variants, we used targeted NGS to identify low-frequency genetic variants. The variants may be useful for improving Tac dosing and understanding Tac trough variability.

Methods {#S2}
=======

Subjects and Tacrolimus Measurements {#S3}
------------------------------------

The 48 subjects identified for EPS and NGS were selected from 345 AAs and 1,443 EAs enrolled in our multi-center prospective, observational trial Deterioration of Kidney Allograft Function (DeKAF) Genomics (clinicaltrials.gov NCT00270712). The study was approved by the Institutional Review Board and informed consent was obtained from each subject prior to entering the study. Although race status was collected by self-reporting, principal components were used to select subjects for the EPS model. GWAS was previously conducted with all subjects. Subjects in the analysis were AA or EA kidney transplant recipients, ≥18 years who received Tac maintenance immunosuppression from 7 centers: University of Minnesota, Hennepin County Medical Center, University of Alabama, Mayo Clinic-Rochester, University of Iowa, University of Manitoba and University of Alberta. Recipient characteristics, clinical outcomes, Tac troughs and doses and concomitant medications were prospectively collected. Oral Tac was initiated around time of transplant using twice daily dosing. Doses were adjusted to achieve each institution's target trough. Tac troughs were measured at each center approximately 12-hours following the last dose, at steady state with the current dose. Generally, troughs of 8-12 ng/mL were targeted for the first 3 months and 6-10 ng/mL for 3-6 months post-transplant. Median (range) of 18 (1-24) troughs were obtained for each subject in the first 6 months post-transplant. Tac trough whole blood measurements were clinically measured at each site and analyzed in CLIA approved laboratories with \>95% measured by liquid chromatography-mass spectrometry.

Genotyping of Subjects {#S4}
----------------------

Before this study, genotyping on all subjects was performed on recipient DNA isolated from peripheral blood with the Affymetrix Transplant GWAS array that has been previously described[@R15]. The EPS model adjusted for common SNPs and principal components data from this array to assign race.

Selection of Subjects for Extreme Phenotype Sampling (EPS) {#S5}
----------------------------------------------------------

To select subjects with the extreme phenotype of Tac troughs, 48 kidney transplant recipients with the 12 highest and 12 lowest Tac troughs from the EA or AA cohorts, after accounting for clinical factors, known common genetic variants and enrolling transplant center, were selected for this study ([Figure 1](#F1){ref-type="fig"}). To select these individuals, linear mixed-effects models (LMMs) were used to test for associations between natural log (ln)-transformed dose-normalized Tac troughs and the LoF genotypes *CYP3A5 \*3* (rs776746), *CYP3A5 \*6* (rs10264272) and *CYP3A5 \*7* (rs41303343) in AAs. For EAs, we adjusted for LoF genotypes *CYP3A5\*3* and *CYP3A4\*22* (rs35599367). Log transformation was used to ensure that the outcome was normally distributed. Our prior analyses found that dose-normalized troughs initially start low, rise quickly until day 9 after transplant and then plateau in the early weeks after transplant[@R12]^,^ [@R16]. Therefore, a simple spline method was used to model the effect of time on all trough concentrations, with the change in slope occurring at day 9. The longitudinal LMMs included a random intercept, random slopes for days after transplant, and days after post-transplant day 9. Confounding fixed clinical factors were retained in the EPS model and were selected by performing backward selection with retention p-value of 0.10. For EAs, we adjusted for factors: time post-transplant, transplant recipient age, weight, diabetes status, living vs. deceased donor, donor gender, and antibody induction type; and time-varying covariates included estimated glomerular filtration rate, steroid use, calcium channel blocker use, angiotensin-converting enzyme inhibitor use and antiviral use. For AAs, we adjusted for time post-transplant, transplant recipient age, simultaneous pancreas and kidney transplant (SPK), and antibody induction type and time-varying covariates glomerular filtration rate (GFR) and antiviral use. The multivariable models were used to determine residuals which were then used to identify the subjects with the extreme phenotypes of adjusted Tac troughs. Analyses were conducted with SAS version 9.2 software (SAS Institute, Cary, NC).

Targeted Next Generation Sequencing (NGS) {#S6}
-----------------------------------------

Hybridization-based capture was performed with 1 μg of genomic DNA with NimbleGen SeqCap EZchoice kit (Roche, NimbleGen). Sequencing spanning the entire length of 28 genes ([Table 1](#T1){ref-type="table"}) was performed and extended \~20,000 base pairs upstream and downstream of these genes. Thus, the extended sequencing length included 42 partial genes adjacent to the 28 genes for a total of 70 genes ([Table 2](#T2){ref-type="table"}) spanning 3,123,443 base pairs. These 28 genes were selected because they were hypothesized as associated with Tac disposition. We used a custom relaxed coverage probe design (Roche NimbleGen) allowing up to 20 close matches in the genome that increased the coverage across all regions. Standard SeqCap EZ gDNA libraries were developed and hybridized with the custom EZ choice probes following standard protocols. The captured libraries were multiplexed and sequenced using MiSeq V2 chemistry (2×150 bp).

Bioinformatics Analysis of NGS Data {#S7}
-----------------------------------

The raw Illumina sequences were evaluated for quality with FASTQC[@R17]. Sequenced reads were aligned to University of California Santa Cruz's human reference genome (GRCH 37/hg 19) with a Burroughs-Wheeler Aligner[@R18]. Depending on the reporting group[@R19]^,^ [@R20], recommended sequence depth is at least 10X-30X; we targeted \>20X depth for making variant calls. Genome Analysis Toolkit's (GATK) best practices[@R21]^-^[@R26] pipeline was used to identify and call variants[@R27]. The final list of variants obtained were annotated with the snpEff tool[@R28] and the Ensembl Variant Effect Predictor (VEP)[@R29]. Variants were evaluated *in silico* by Sorting Intolerant from Tolerant (SIFT)[@R30]^,^ [@R31] and Polymorphism Phenotyping Tool 2 (PolyPhen2)[@R32]^-^[@R34] to assess potential impact on protein.

Statistical Analysis of Extreme Phenotype Individuals {#S8}
-----------------------------------------------------

A logistic regression model was applied, as cases and controls were identified as low versus high dose-normalized Tac trough subjects respectively, in either AA or EA groups. Due to small sample size, tests for association were performed by permutation testing and p-values were calculated. A continuous trait test was performed by regressing the dose-normalized Tac troughs on the genetic variants accounting for the selection procedure. Thus, two types of analyses were performed: **A)** Association tests for each of the single genetic variants with both EA and AA groups to determine SNPs associated with Tac metabolism in each group. **B)** Gene based test on 70 genes ([Table 2](#T2){ref-type="table"}) with burden test (BT) (linear sum of variant scores test), sequence kernel association test (SKAT) (sum of squared variant based test), and an optimal combination of BT and SKAT (SKATO)[@R35]. P-values were further Bonferroni corrected with significance level of 0.0007 for the gene-based test. Focused-SNP set analyses, with each subject group, were performed on SIFT and PolyPhen2 selected variants which were predicted to impact protein function.

Manual Curation of Genetic Variants to Identify Genetic Variants {#S9}
----------------------------------------------------------------

We manually inspected variants identified by GATK analysis in the Tac related genes *CYP3A4*, *CYP3A5, POR* and *CYB5A* for previously unidentified genetic variants in the 5'-untranslated regions (UTR), exons and 3'-UTR regions of these genes in our EPS model cohorts.

Results {#S10}
=======

Subject characteristics are described in [Table 3](#T3){ref-type="table"}. The EPS model in [Figure 2](#F2){ref-type="fig"} shows the natural-log of dose-normalized Tac troughs from the groups over the first 6-months post-transplant. As expected, the EA high group had the highest dose-normalized Tac troughs over time. The AA high group had the next highest Tac troughs, third was the EA low group and the AA low group had lowest Tac troughs. The subjects with 2 known LoFs could have any combination of *CYP3A5 \*3*, *\*6*, *\*7* or *CYP3A4 \*22* alleles. After adjusting for *CYP3A5 \*3*, *\*6*, and *\*7* in the AA high group 6 subjects had 2 known LoFs, while the AA low group had 1 subject with 2 known LoFs ([Table 3](#T3){ref-type="table"}). After adjusting for *CYP3A5 \*3* and *CYP3A4 \*22* alleles*,* the EA high group had 11 subjects with 2 known LoFs and the EA low group had 10 subjects with 2 known LoFs. Since the EPS model adjusted for common LoF genetic variants, these groups may have complex genetics associated with Tac disposition.

Data Availability {#S11}
-----------------

Raw sequence data, in fastq format, are available at the United States National Center for Biotechnology Information's (NCBI) Sequence Read Archive (SRA) with SRA accession number: SRP156752. The associated phenotype and covariate data are available at NCBI's Database for Genotypes and Phenotypes with dbGaP accession number: phs001670.v1.p1.

Variants Identified from Sequencing {#S12}
-----------------------------------

The estimated coverage of NimbleGen sequencing was 86.6% of the total bases across the entire genetic distance of 28 genes. The remaining 13.4% were not covered because of the repetitive nature of the genomic regions. The sequencing depth was 60X across these 28 genes and 42 adjacent partial genes after mapping and quality control filtering of the sequences. The sequencing of the 42 partial genes did not span the entire length of those genes. A total of 18,661 variants in 48 extreme phenotype subjects were identified and processed for quality. With the Variant Effect Predictor (VEP) tool [@R29], out of the 18,661 total variants identified, 3,961 variants (21.2%) were unknown and 14,700 (78.8%) were previously identified. The VEP analysis of these variants, and the coding variants, based on their predicted consequences are described in [Figure 3](#F3){ref-type="fig"}. Although many of the genetic variants had unspecified significance, we identified 15,948 variants in the AA cohort and 11,074 variants in the EA cohort that were different (alternative allele) than the reference genome GRCH 37/hg 19.

Statistical Association of Variants Identified through Sequencing with Tac Troughs {#S13}
----------------------------------------------------------------------------------

The association testing identified 397 and 297 variants that were associated with dose-normalized Tac troughs in AA and EA, respectively, with p\<0.05 by either case-control or continuous trait tests. However, 15 ([Table 4](#T4){ref-type="table"}) and 9 ([Table 5](#T5){ref-type="table"}) variants in AA or EA, respectively had a p\<0.005. Variants identified in the EA cohort with p\<0.005 were in *ABCC1, ANAPC10, NR3C1* and *OTUD4*. Variants identified in the AA cohort with p\<0.005 were in *ADIPOR1*, *CYB5R2*, *OVCH2* and *POR*.

SIFT and PolyPhen2 analysis of identified genetic variants {#S14}
----------------------------------------------------------

SIFT[@R30]^,^ [@R31] analysis was conducted on all the genetic variants identified in the 48 subjects. Of the 18,661 identified genetic variants, 125 were determined to be deleterious, 22 were deleterious-low confidence while the remaining variants were tolerated.

PolyPhen2[@R32]^-^[@R34] analysis was also performed on genetic variants. Of the 18,661 genetic variants, 110 were determined to be probably damaging, 63 of the variants were determined to be possibly damaging and the remaining variants were benign.

[Figure 4](#F4){ref-type="fig"} shows a Venn diagram of the SIFT and PolyPhen2 results of variants predicted to impact protein function. We discovered 69 genetic variants classified as both deleterious by SIFT and probably damaging by PolyPhen2. These 69 genetic variants ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}) have the highest likelihood of affecting protein function and thus may also affect Tac disposition.

SKAT Gene Based Test Identified CYP5R2 Association with Tac Disposition in African American Cohort {#S15}
--------------------------------------------------------------------------------------------------

By using SKAT[@R36]^-^[@R39] to test the gene-level association with the continuous trait of dose-normalized Tac troughs, the most significant gene associated with Tac troughs in AA subjects was *CYB5R2* by SKAT after Bonferroni correction (p=7.9×10^-4^). *CYB5R2* was also significant by SKAT by case-control test (p=8.5×10^-4^). None of the genes were significantly associated with the EA cohort. Of the 525 variants identified in *CYB5R2* (including upstream and downstream), 4 of these variants were found within the *CYB5R2* gene that were predicted to functionally impact protein function according to SIFT or PolyPhen2 ([Table 6](#T6){ref-type="table"}). The genetic variant identified in *CYB5R2* most likely to disrupt protein function was rs61733057 (Leu163Trp) because it is predicted as deleterious by SIFT and probably damaging by PolyPhen2. As seen in [Table 6](#T6){ref-type="table"}, the missense A to C variant rs61733057, in *CYB5R2*, has a global allele frequency of 0.05, but has increased allele frequency in both Africans (0.106) and AAs (0.119) compared with EAs (0.048). Likewise, rs61733056 is more frequent in AAs. CYB5R2 is a possible co-enzyme that may supply reducing equivalents to P450, although it is generally thought that CYB5R3 functions by supplying the second electron into the P450 cycle.

Focused SNP-set Analysis for Association in the EA and AA Cohorts {#S16}
-----------------------------------------------------------------

Genetic variants were further analyzed to detect association with dose-normalized Tac troughs within the AA or EA cohorts. The SNPs analyzed by SIFT and Polyphen2, with predicted impact on protein function, were grouped into 4 categories: **1.)** Polyphen2: probably damaging (N=110) ([Supplemental Table 2](#SD1){ref-type="supplementary-material"}) **2.)** PolyPhen2: possibly damaging (N=63) ([Supplemental Table 3](#SD1){ref-type="supplementary-material"}) **3.)** SIFT: deleterious (N=125) ([Supplemental Table 4](#SD1){ref-type="supplementary-material"}) **4.)** SIFT: deleterious-low confidence (N=22) ([Supplemental Table 5](#SD1){ref-type="supplementary-material"}). These 4 categories of variants were tested by BT, SKAT, and SKATO for association with the EA and AA cohorts, separately. The group of 125 predicted deleterious variants ([Supplemental Table 4](#SD1){ref-type="supplementary-material"}) from SIFT had significant association with the EA cohort (BT, p=0.008) by case-control test.

Variants Observed During Manual Inspection of Variants {#S17}
------------------------------------------------------

We examined SNPs in *CYP3A4*, *CYP3A5, POR* and *CYB5A genes*. We found several SNPs in the 5'-UTR of *CYP3A4* and *CYP3A5* that could affect protein expression. Surprisingly, we identified synonymous and non-synonymous SNPs with no reported rs numbers in dbSNP database in *POR*. In contrast, only a single previously unreported non-synonymous variant, His44Asn in exon 2 was identified in *CYB5A*, along with 16 previously unreported SNPs in the first 2,300bp upstream in the 5'-UTR. These variants are shown in [Supplemental Table 6](#SD1){ref-type="supplementary-material"} (*CYP3A4*)**,** [Supplemental Table 7](#SD1){ref-type="supplementary-material"} (*CYP3A5*)**,** [Supplemental Table 8](#SD1){ref-type="supplementary-material"} *(POR*) and [Supplemental Table 9](#SD1){ref-type="supplementary-material"} (*CYB5A*).

Discussion {#S18}
==========

This study showed that an EPS model and NGS identified 18,661 genetic variants associated with Tac disposition in 48 extreme phenotype subjects. VEP analysis determined 3,961 variants (21.2%) were unknown and 14,700 (78.8%) were previously known. We found 125 genetic variants that were predicted as deleterious of protein function by SIFT analysis and were significantly associated with Tac disposition in the EA group (BT, p=0.008). We further found 110 genetic variants that were probably damaging to protein function by PolyPhen2. Of these variants, 69 were also deleterious according to SIFT analysis and would represent the genetic variants most likely to affect protein function, and thus Tac disposition. For our studies, individual variant analysis lacks power due to small sample size with very limited number of genotype counts. Though some individual variants in a gene have weak signals, combining them can lead to a significant result as done in SKAT. Thus, a major finding was the significant association of *CYB5R2* with Tac troughs in AAs by SKAT analysis. The genetic variant, rs61733057, in the *CYB5R2* gene, was identified and predicted to be deleterious by SIFT and probably damaging by PolyPhen2. Thus, we have identified variants associated with Tac troughs in kidney transplant recipients that require future *in vitro* assessment or validation in another cohort.

At the time of this study, it was not feasible to determine low-frequency variants, by sequencing all subjects because that required NGS of thousands of subjects. Therefore, we used an EPS approach that was successful to identify low-frequency variants in other diseases[@R40],[@R41],[@R42],[@R43],[@R44],[@R45]. Previous research suggests sampling from both high and low extremes is important to identify variants associated with a particular phenotype[@R45]. This EPS approach allows for smaller sample sizes to identify low-frequency genetic variants associated with a phenotype[@R14]. Thus, our study corroborates other studies showing that the EPS approach can identify genetic variants, or genes, which are associated with a phenotype. This EPS approach can save time and money by sampling fewer subjects.

Genetic Variants associated with Tac metabolism were identified and shown in [Table 4](#T4){ref-type="table"} (AA) and [Table 5](#T5){ref-type="table"} (EA). [Table 4](#T4){ref-type="table"} shows single genetic variants associated with Tac metabolism in AAs. Many of these variants were in *POR* which encodes for a coenzyme involved in cytochrome P450 metabolism. The variants in *OVCH2* are upstream, and likely in the promotor, of *CYB5R2*. A single variant found in *ADIPOR1*, was likely identified since it is downstream of the gene *CYB5R1*. Additionally, [Table 5](#T5){ref-type="table"} has genetic variants associated with Tac metabolism in EAs. The variants identified were in the genes *OTUD4*, *NR3C1*, *ABCC1*, upstream of *HNF4A* and *ANAPC10*. The variant in *ANAPC10* was also located in the 5'-UTR of *ABCE1* gene. The *OTUD4* variants are located in the 3'-UTR of *ABCE1*. *ABCE1* is an ATP-binding cassette protein but lacks the transmembrane domain needed for transporter function. *ABCE1* functions as a ribonuclease L inhibitor where it associates with the ribosome and initiation factors elF3 and elF5. We speculate that this would lead to less mRNA transcription, and reduce protein expression but that may be non-specific for *CYP3A4* and *CYP3A5*. The variant found in the glucocorticoid receptor *NR3C1*, a transcription factor that can influence the expression of PXR, which in turn regulates *CYP3A4* and *CYP3A5*. The other variant found in AAs was in the *ABCC1* gene which may be involved in Tac transport. In general, functional assays will be needed to validate the association of these variants with Tac metabolism.

[Table 6](#T6){ref-type="table"} shows 4 variants found in *CYB5R2* and indicates *CYB5R2* to be associated with Tac metabolism in AAs. *CYB5R2* has not previously been associated with Tac troughs, disposition or metabolism, but was unexpectedly identified in AAs with extreme Tac troughs. *CYB5R2,* (in chromosome 11), differs from its homolog *CYB5R3* (in chromosome 22), but share high sequence identity and there is limited literature regarding *CYB5R2*. Both CYB5R2 and CYB5R3 can reduce cytochrome b5 and act as co-factors for cytochrome P450 function (supply electrons into the P450 cycle). While CYB5R2 is located in the nucleus, CYB5R3 is present in the endoplasmic reticulum in liver. CYB5R3 exists in two forms as a membrane-bound variant in membranes including in erythrocytes where low activity variants have been associated with methemoglobinemia and a truncated soluble cytoplasmic form containing the FAD catalytic domain. *CYB5R2* has been identified as a tumor suppressor that is epigenetically regulated[@R46]. *CYB5R2* negatively regulates vascular endothelial growth factor[@R47] which could contribute to its tumor suppressor activity. Furthermore, *CYB5R2* is epigenetically regulated through promoter methylation[@R48], associated with patient survival of glioblastoma, and functions in collagen maturation, immunoregulation via toll-like receptor pathways, and osmotic stress[@R49]. The *CYB5R2* variant, rs61733057, that likely impacts *CYB5R2* protein function, was identified. It has elevated frequency in the AAs compared with EAs. According to 1000 genomes database ([Table 6](#T6){ref-type="table"}), the identified variants associated with Tac troughs in AAs rs61733057 and rs61733056 are primarily in people of African descent, which would corroborate our finding of this variant in AAs. However, with limited *CYB5R2* literature it is difficult to determine its function in Tac disposition.

This study identified genetic variants in *CYP3A4*, *CYP3A5*, *POR* and *CYB5A*. Although many of these variants ([Supplemental Tables 6-9](#SD1){ref-type="supplementary-material"}) did not show significant association with Tac troughs in our analysis, numerous naturally occurring genetic variants were identified that have not been reported. Many of these variants were in the 5' and 3'-UTR regions of *CYP3A4* and *CYP3A5*. We identified 1 exonic SNP in *CYP3A4* with gene position 1022 A\>G which would lead to amino acid substitution Lys341Arg. We identified multiple non-synonymous SNPs in *POR* without rs numbers. More than 160 *POR* variants have been described to be associated with altered steroid metabolism and Antley-Bixler syndrome and disordered steroidogenesis. Five of the novel *POR* variants appeared only in single individuals with high Tac troughs, namely Arg186Val, Asp473Tyr, Gly589Val and Ala661Ser in the EA high group and Arg453Ser in the AA high group. If these SNPs result in lowered transfer of electrons into the P450 cycle, one would expect reduced clearance via CYP3A4 and CYP3A5.

We recently developed an *in vitro* method to validate the association of genetic variants with drug metabolism[@R50]. Variants are genetically engineered into cell lines, using CRISPR/Cas9, and then the cells are assayed to determine the effect of the specific variant on drug metabolism. This method was successfully used to validate the effect of *CYP3A5 \*1* vs. *CYP3A5 \*3* (rs776746) alleles on Tac metabolism[@R50]. This method can be used to engineer variants, identified in this study, into a hepatocyte cell lines to study Tac metabolism.

This study had limitations. Although we sequenced numerous genes expected to be associated with Tac troughs, whole genome sequencing would have been more complete. However, there were considerable cost differences between whole genome sequencing and targeted NGS. A *FOXP3* genetic variant, rs3761548, was reported to be associated with Tac troughs[@R51] and we did not sequence *FOXP3*. Another limitation of this study is that SIFT and PolyPhen2 are not completely accurate prediction algorithms. One study found, for missense variants in G protein couple receptor genes, that SIFT and PolyPhen2 were 83% and 85% accurate, respectively; while the LoF prediction was over 90% accurate for both, predicting non-functional variants was 54 or 57% accurate, respectively[@R52]. One study investigated the accuracy of SIFT and PolyPhen2 for predicting missense mutations in *BRCA1*, *MSH2*, *MLH1* and *TP53* genes that resulted in area under the curve of receiver operating characteristic curves for both algorithms to be between 78 and 79%[@R53]. Another study has shown that SIFT, PolyPhen2 and other predictive *in silico* tools' accuracy is gene dependent and also best when used in combination[@R54]. Thus, we focused on the identified variants in this study that were identified to disrupt protein function by both SIFT and PolyPhen2. A further limitation that we did not consider was Tac adherence because adherence data was not collected. Due to the limited number of subjects in each group (N=48, 4 groups of 12), additional statistical power would be gained by sequencing more subjects. Although, there are limitations to this study, this model was effective at identifying genetic variants associated with Tac metabolism in kidney transplant recipients.

We envision expanding this study with more subjects to identify more genetic variants. We foresee these genetic variants being translated into refined Tac dosing equations[@R8]^,^ [@R9]. Refined dosing equations could be used to reduce variability in Tac troughs while reaching optimal therapeutic Tac troughs quickly post-transplant to reduce poor outcomes.
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![Extreme Phenotype Sampling (EPS) Model to Detect Genetic Variants Associated with Tacrolimus Metabolism from African American (AA) or European American (EA) Kidney Transplant Recipients.\
The graphs represent the mean dose-normalized Tac troughs on the y-axis and the distribution of subjects on the x-axis. The 12 recipients with highest or lowest Tac troughs, after adjusting for clinical variables and common genetic variants, from each group were selected for targeted next generation sequencing (NGS). **A.** The model used to select AA kidney transplant recipients was adjusted for genetic variants *CYP3A5 \*3*, *\*6*, and *\*7*. The 12 AA subjects with the highest (3.5%) or 12 with the lowest (3.5%) Tac troughs were used for NGS from a cohort of 345 total subjects. **B.** The model used to select EA kidney transplant recipients was adjusted for genetic variants *CYP3A5 \*3* and *CYP3A4 \*22*. The 12 EA subjects with the highest (0.8%) or 12 with the lowest (0.8%) dose-normalized Tac troughs were used for NGS from a cohort of 1,443 total subjects.](nihms-1508276-f0001){#F1}

![Dose Normalized Tac Troughs of Subjects from Extreme Phenotype Sampling (EPS) Model used for Next Generation Sequencing (NGS).\
The figure shows natural log transformed Tac dose-normalized troughs over time, in high and low AA or EA Tac groups. Data lines represent smoothed conditional means and gray areas represent 95% confidence intervals. The 12 EA subjects with the highest (0.8%) or 12 with the lowest (0.8%) Tac troughs were used for NGS from a cohort of 1,443 total subjects. The 12 EA subjects with the highest (3.5%) or 12 with the lowest (3.5%) Tac troughs were used for NGS from a cohort of 345 total subjects after adjustment for known genotypes and clinical factors.](nihms-1508276-f0002){#F2}

![Variant Effect Predictor (VEP) results based on genetic variants identified\
A. Predicted consequences of the 18,661 genetic variants identified in this sequencing study. **B.** Predicted gene expression consequences from coding sequences in the VEP analysis.](nihms-1508276-f0003){#F3}

![SIFT and PolyPhen2 Results of all 18,661 variants in a Venn diagram\
SIFT and PolyPhen2 are bioinformatics analytic tools that predict the affect specific genetic variants may have on protein function. Of the 18,661 variants, 125 were deleterious and 22 were deleterious with low confidence by SIFT while the remaining variants were tolerated. Polyphen2 analysis found 110 of the variants were probably damaging, 63 were possibly damaging while the remaining variants were benign to impacting protein.](nihms-1508276-f0004){#F4}

###### 

Full Genes Sequenced in this Study

  Gene                        Protein Name                                                           Function and Relevant References Showing Association with Tac Disposition
  --------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *CYP3A locus*               Cytochrome P450 subfamily: CYP3A4, CYP3A5, CYP3A43, CYP3A7, CYP3A51P   Metabolism of Tac [@R55]^-^[@R58]
  *CYP2J2*                    Cytochrome P450, subfamily 2J polypeptide 2                            P450 enzyme expressed in intestine, heart. Drug metabolism. Metabolizes arachidonic acid promoting kidney homeostasis, Tac has inhibitory effect nephrotoxicity [@R59]^,^ [@R60]
  **Co-enzymes**                                                                                     
  *POR*                       cytochrome P450 oxidoreductase                                         P450 oxidoreductase and reduced cytochrome b5 supply electrons into the P450 cycle. Addition of cyt b5 stimulates CYP3A4 activity *in vitro*. Oxidoreductase responsible for electron transfer from NAD to CYP450, (POR\*28 is associated with increased CYP3A activity and increase Tac clearance) [@R61]^-^[@R63]
  *CYB5A*                     Cytochrome B5, TypeA                                                   Participant in the CYP450 cycle as an electron donor for cytochrome b5. Drug metabolism
  *CYB5R1*                    NADH-Cytochrome B5 Reductase                                           Reduces cytochrome b5. Cytochrome b5 donates second electron in P450 cycle and enhances CYP3A activity.
  *CYB5R2*                    NADH-Cytochrome B5 Reductase-2                                         Bifunctional reductase that contains cytochrome b5 and reductase domains in same protein. Cytosolic enzyme. Unclear if it associated with P450.
  *CYB5R3*                    Cytochrome B5 Reductase 3                                              Participant in CYP450 cycle as electron donor for cytochrome b5. Drug metabolism [@R64], Present in endoplasmic reticulum membrane
  *CYB5R4*                    NADH-Cytochrome B5 Reductase-4                                         Reduces cytochrome b5. Cytochrome b5 supplies second electron in P450 cycle and stimulates CYP3A activity.
  *CYB5RL*                    NADH-Cytochrome B5 Reductase-Like                                      Reduces cytochrome b5
  *CYB5D1*                    Cytochrome B5 Domain-Containing Protein-1                              Serves as an electron donor for cytochrome b5 and thus participates in CYP450 cycle. Thus, play a role in drug metabolism
  ***Transporters***                                                                                 
  *ABCB1*                     ATP-Binding Cassette, Subfamily B, member 1                            Efflux transporter known as Multi Drug Resistance1 or P-glycoprotein. Tac is a substrate. Actively transports Tac into the intestinal lumen as a counter-transport pump [@R65]^-^[@R67]
  *ABCC1*                     ATP-Binding Cassette, subfamily C, member 1                            Efflux transporter. Also known as Multidrug resistance associated protein 1 (MRP1). Findings suggest that MDR1 polymorphisms has effect on Tac pharmacodynamics [@R68]^-^[@R70]
  *ABCC2*                     ATP-Binding Cassette, subfamily C, member 2                            Efflux transporter also known as Multidrug resistance associated protein 2 (MRP2) [@R71].
  *ABCG2*                     ATP-Binding Cassette, Subfamily G, member 2                            Efflux transporter, also named Breast Cancer Resistance Protein. Tac is a inhibitor, variants in ABC transporter gene may also associate with Tac pharmacokinetics [@R67]
  *ABCE1*                     ATP-Binding Cassette, Subfamily E, member 1                            Efflux transporter also known as ribonuclease 4 inhibitor
  *SLCO1B3*                   Solute Carrier Organic anion transporter family, member 1B3            Uptake transporter for organic anions. Also known as OATP1B3.
  **Transcription Factors**                                                                          
  *VDR*                       Vitamin D Receptor                                                     Ligand activated transcription factors) that control gene expression). Highly expressed in intestine, but not in liver. Affects intestinal expression of CYP3A [@R72]
  *NR3C1(GR)*                 Nuclear Receptor Subfamily 3, group Member 1                           Glucocorticoid Receptor. Glucocorticoid-activated transcription factor that controls gene expression (several drug metabolizing genes contain GR response elements) [@R73]
  *NR1I2(PXR)*                Nuclear Receptor Subfamily 1, group 1, Member 2                        Pregnane X Receptor. Ligand activated transcription factors) that control gene expression Regulates expression of drug metabolizing enzymes and drug transporters in liver [@R62]^,^ [@R74]^,^ [@R75]
  *NR1I3(CAR)*                Nuclear Receptor Subfamily 1, group 1, Member 3                        Constitutive Androstane Receptor. Ligand-activated transcription factors) that control gene expression. Alters expression of CYP3A genes. Key regulator of drug metabolizing enzymes and drug transporters [@R76]
  *HNF4A*                     Hepatocyte Nuclear Factor-4-α                                          Transcription factor for hepatic gene expression regulation, Regulates PXR and CAR expression and CYP3A expression[@R77]
  *CEBPA*                     C/EBP-Alpha                                                            Co-factor (activator) for gene regulation. Especially transporters ABBC2 and ABCB1 [@R78]^,^ [@R79]
  *CEBPB*                     CCAAT/Enhancer Binding Protein, Beta                                   Co-factor (activator) for gene regulation. Especially transporters ABBC2 and ABCB1
  *PPARA*                     Peroxisome Proliferator-Activator Receptor Alpha                       Has regulatory effect on CYP3A4 expression [@R62]^,^ [@R80]^,^ [@R81]
  *FOXA2*                     Forkhead Box protein A2                                                Transcription factor also named HNF3-β, has effect on hepatic *CYP3A4* expression[@R82]
  *NCOR1*                     Nuclear Receptor Corepressor 1                                         Co-factor (repressor) for gene regulation. Associated with transporters ABBC2 and ABCB1
  *YY1*                       Transcriptional Repressor Protein                                      Downregulates Cytochrome c Oxidase and *CYP3A4* and *CYP3A5*

Note: Each gene was sequenced 20 kilobases upstream and downstream of the gene.

###### List of all 70 genes used in the gene based statistical test

Since we sequenced 20 kb upstream and downstream, and spanning the entire length of 28 genes in [Table 1](#T1){ref-type="table"}, this led to partial sequencing of 42 genes adjacent to these 28 genes and thus 70 total genes.

  ----------- ---------------- ----------- ----------
  ABCB1       CYB5D2           LOC401980   PPFIBP2
  ABCC1       CYB5R1           LSMD1       R3HDML
  ABCC2       CYB5R2           MAATS1      RIPPLY2
  ABCC6       CYB5R3           MRPL37      RNU12
  ABCE1       CYB5R4           NCOR1       RUNDC3B
  ABCG2       CYB5RL           NDUFS2      SLC25A29
  ADIPOR1     CYP2J2           NR1I2       SLCO1B3
  ANAPC10     CYP3A4           NR1I3       STYXL1
  ANKFY1      CYP3A43          NR3C1       TMEM120A
  APOA2       CYP3A5           OR2AE1      TMEM88
  CDCP2       CYP3A7-CYP3AP1   OTUD4       TOMM40L
  CDPF1       FCER1G           OVCH2       TTC19
  CEBPA       FOXA2            PIGL        VDR
  CEBPA-AS1   GSK3B            PKD2        YY1
  CEBPB       HNF4A            PKDREJ      ZSCAN25
  CHD3        HOOK1            POLDIP3     ZZEF1
  YB5A        KDM6B            POR          
  CYB5D1      LINC00261        PPARA        
  ----------- ---------------- ----------- ----------

###### Clinical and Genetic Characteristics of the Extreme Phenotype Subjects in African American (AA) and European American (EA) Groups.

The High groups had the highest dose-normalized Tac troughs, while the Low groups had the lowest dose normalized Tac troughs. AA cohort N=345 and EA cohort N=1443.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------- ------------------ ---------------- ------------------
  **Age**                                                                                                                                                                                                                                **18-34**        2                 2                  1                0
  **35-64**                                                                                                                                                                                                                              9                10                8                  10               
  **65-84**                                                                                                                                                                                                                              1                0                 3                  2                
  **Diabetes**                                                                                                                                                                                                                           **yes**          6                 9                  9                7
  **no**                                                                                                                                                                                                                                 6                3                 3                  5                
  **Donor Status**                                                                                                                                                                                                                       **Living**       2                 8                  11               7
  **Deceased**                                                                                                                                                                                                                           10               4                 1                  5                
  **Donor Gender**                                                                                                                                                                                                                       **Male**         7                 4                  7                10
  **Female**                                                                                                                                                                                                                             5                8                 5                  2                
  **Number of subjects with *CYP3A5*[\*](#TFN2){ref-type="table-fn"}*3* Allelesrs776746_G**                                                                                                                                              **0**            5                 4                  0                0
  **1**                                                                                                                                                                                                                                  6                7                 1                  2                
  **2**                                                                                                                                                                                                                                  1                1                 11                 10               
  **Number of subjects with *CYP3A5*[\*](#TFN2){ref-type="table-fn"}*6* Allelesrs10264272_T**                                                                                                                                            **0**            10                10                 12               12
  **1**                                                                                                                                                                                                                                  1                2                 0                  0                
  **2**                                                                                                                                                                                                                                  1                0                 0                  0                
  **Number of subjects with *CYP3A5*[\*](#TFN2){ref-type="table-fn"}*7* Allelesrs41303343_TA**                                                                                                                                           **0**            8                 11                 12               12
  **1**                                                                                                                                                                                                                                  3                1                 0                  0                
  **2**                                                                                                                                                                                                                                  1                0                 0                  0                
  **Number of subjects with *CYP3A4*[\*](#TFN2){ref-type="table-fn"}*22* Allelesrs35599367_A**                                                                                                                                           **0**            11                12                 10               11
  **1**                                                                                                                                                                                                                                  1                0                 2                  1                
  **2**                                                                                                                                                                                                                                  0                0                 0                  0                
  **Number of subjects with known CYP3A Loss of Function Alleles (*CYP3A5*[\*](#TFN2){ref-type="table-fn"}*3*,[\*](#TFN2){ref-type="table-fn"}*6*,[\*](#TFN2){ref-type="table-fn"}7 or *CYP3A4*[\*](#TFN2){ref-type="table-fn"}*22*)**   **0**            2                 1                  0                0
  **1**                                                                                                                                                                                                                                  4                10                1                  2                
  **2**                                                                                                                                                                                                                                  6                1                 11                 10               
  **Estimated GlomerularFiltration Rate[\*](#TFN2){ref-type="table-fn"}(mL/min)**                                                                                                                                                        **\< 54.9**      19.9%             9.1%               19.0%            31.6%
  **54.9-67.9**                                                                                                                                                                                                                          11.7%            45.7%             28.8%              27.0%            
  **67.9-83.5**                                                                                                                                                                                                                          24.5%            17.8%             22.3%              20.9%            
  **\>83.5**                                                                                                                                                                                                                             43.9%            27.4%             29.9%              20.5%            
  **Weight (kg)[\*](#TFN2){ref-type="table-fn"}**                                                                                                                                                                                        **\< 69.4**      26.5%             4.6%               56.5%            20.5%
  **69.4-80.9**                                                                                                                                                                                                                          20.9%            12.8%             28.3%              49.3%            
  **80.9-94.6**                                                                                                                                                                                                                          32.7%            21.0%             12.0%              0.9%             
  **\>94.6**                                                                                                                                                                                                                             19.9%            61.6%             3.3%               29.3%            
  **Steroid Use in First 6 Months**                                                                                                                                                                                                      **Yes**          11                11                 12               12
  **No**                                                                                                                                                                                                                                 1                1                 0                  0                
  **Simultaneous Pancreas andKidney Transplant**                                                                                                                                                                                         **Yes**          1                 0                  0                1
  **No**                                                                                                                                                                                                                                 11               12                12                 11               
  **Antibody Induction**                                                                                                                                                                                                                 **Monoclonal**   8                 5                  5                3
  **Polyclonal**                                                                                                                                                                                                                         4                7                 7                  8                
  **Calcium ChannelBlocker in First 6 Months**                                                                                                                                                                                           **Yes**          8                 9                  5                9
  **No**                                                                                                                                                                                                                                 4                3                 7                  3                
  **ACE Inhibitor in First 6 Months**                                                                                                                                                                                                    **Yes**          4                 4                  5                2
  **No**                                                                                                                                                                                                                                 8                8                 7                  10               
  **Antiviral Use in First 6 Months**                                                                                                                                                                                                    **Yes**          12                9                  12               11
  **No**                                                                                                                                                                                                                                 0                3                 0                  1                
  **Tac Daily Dose (mg)Median (range)**                                                                                                                                                                                                                   4.0(0.5 - 12.0)   14.0(1.0 - 36.0)   1.0(0.1 - 6.0)   14.0(2.0 - 36.0)
  **Tac Trough Concentration (ng/mL)Median (range)[\*\*](#TFN3){ref-type="table-fn"}**                                                                                                                                                                    7.5(1.0 - 21)     5.1(1.0 -18)       8.9(2.4 - 26)    8.1(1.3 - 29)
  **Dose Normalized Tac Trough Concentration (ng/mL)Median (range)**                                                                                                                                                                                      2.4(0.3-31)       0.38(.083-1.4)     7.7(1.0-82)      0.57(0.13-4.8)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------- ------------------ ---------------- ------------------

Estimated Glomerular Filtration Rate and Weight are for time point closest to the corresponding Tac trough measurement

Tac troughs, and dose normalized Tac troughs, were measured periodically for each subject, up to 24 times per subject.

###### Single Variants Associated with Dose- Normalized Tacrolimus Troughs, identified in African American Kidney Transplant Recipients (p\<0.005).

The table indicates the chromosome location of the variants based on GRCH37 assembly, the variant alternate allele, the consequence effect of the variant on the Ensembl transcripts, the gene symbol, the exon number out of the total number of exon in that gene, the intron number out of the total number in that gene, Existing known variants' rs number if available and the allele frequencies from 1000 Genomes project as given by VEP software. AF = global, AFR = African population, AMR = American population, EUR = European population, EAS = East Asian population, SAS = South Asian population, AA = Allele Frequency from in African American population from Lung and Blood Institute-Exome Sequencing Project (NHLBI-ESP), EA = Allele Frequency in European American population from NHLBI-ESP. Also shown are the related test p-values for association with Tac troughs.

  Location                Allele      Consequence                                 Symbol      Exon    Intron   Existing_variation    Allele frequencies   Pvalb[^1^](#TFN5){ref-type="table-fn"}   Pvalc[^2^](#TFN6){ref-type="table-fn"}                        
  ----------------------- ----------- ------------------------------------------- ----------- ------- -------- --------------------- -------------------- ---------------------------------------- ---------------------------------------- ------ ------ ------ ------
  7:75552252-75552252     A           intron_variant                              *POR*       \-      1/14     \-                    \-                   \-                                       \-                                       \-     \-     \-     \-
  7:75558027-75558037     C           intron_variant                              *POR*       \-      1/14     rs66811056            \-                   \-                                       \-                                       \-     \-     \-     \-
  7:75573951-75573956     GTGTTTGTT   intron_variant                              *POR*       \-      1/14     rs67675959            0.26                 0.52                                     0.24                                     0.25   0.09   0.10   \-
  7:75576956-75576956     T           intron_variant                              *POR*       \-      1/14     rs239955              0.26                 0.52                                     0.24                                     0.25   0.09   0.10   \-
  7:75565740-75565740     A           intron_variant                              *POR*       \-      1/14     rs239960              0.25                 0.49                                     0.24                                     0.25   0.09   0.10   \-
  11:7710178-7710178      T           downstream_gene_variant                     *OVCH2*     \-      \-       rs4501973             0.46                 0.18                                     0.57                                     0.58   0.61   0.49   \-
  11:7711872-7711872      C           downstream_gene_variant                     *OVCH2*     \-      \-       rs10839842            0.47                 0.18                                     0.57                                     0.59   0.62   0.50   \-
  11:7712471-7712471      T           stop_gained                                 *OVCH2*     15/15   \-       rs4509745             0.48                 0.23                                     0.58                                     0.59   0.62   0.49   0.31
  1:202931839-202931839   A           upstream_gene_variant                       *ADIPOR1*   \-      \-       rs2232854             0.31                 0.18                                     0.40                                     0.43   0.35   0.28   0.23
  7:75544455-75544455     C           upstream_gene_variant                       *POR*       \-      \-       rs3823884             0.48                 0.94                                     0.42                                     0.27   0.27   0.35   \-
  11:7687305-7687305      T           intron_variant                              *CYB5R2*    \-      8/8      rs12794507            0.26                 0.44                                     0.18                                     0.14   0.25   0.22   \-
  7:75586536-75586536     C           intron_variant                              *POR*       \-      2/14     rs4728533             0.73                 0.48                                     0.76                                     0.74   0.91   0.84   \-
  7:75563682-75563682     G           intron_variant                              *POR*       \-      1/14     rs12533235            0.26                 0.52                                     0.24                                     0.25   0.09   0.10   \-
  11:7687517-7687517      C           intron_variant                              *CYB5R2*    \-      8/8      rs11041523            0.49                 0.30                                     0.49                                     0.68   0.51   0.53   \-
  11:7686602-7686606      TGTTTGTT    stop_retained_variant,3_prime_UTR_variant   *CYB5R2*    9/9     \-       rs536512597,rs16411   0.47                 0.26                                     0.49                                     0.64   0.51   0.53   0.28

-Tac troughs were adjusted in the extreme phenotype model for clinical variables and genotypes *CYP3A5\*3*, *CYP3A5\*6,* and *CYP3A5\*7*.

Pvalb: Logistic regression with permutation applied to calculate p-value in the case-control trait test.

Pvalc: Linear regression applied to obtain p-values in the continuous trait test

###### Single Variants Associated with Tacrolimus Adjusted Troughs, Identified in European American Kidney Transplant Recipients of (p\<0.005).

The table indicates the chromosome location of the variants based on GRCH37 assembly, the variant alternate allele, the consequence effect of the variant on the Ensembl transcripts, the gene symbol, the intron number out of the total number in the gene, Existing known variants' rs numbers if available and the allele frequencies from 1000 Genomes project as given by VEP software. AF = global, AFR = African population, AMR = American population, EUR = European population, EAS = East Asian population, SAS = South Asian population. Also shown are the related test p-values for association with Tac troughs.

  Location                Allele   Consequence               Symbol               Intron   Existing_variation   Allele frequencies   Pvalb[^1^](#TFN8){ref-type="table-fn"}   Pvalc[^2^](#TFN9){ref-type="table-fn"}                                
  ----------------------- -------- ------------------------- -------------------- -------- -------------------- -------------------- ---------------------------------------- ---------------------------------------- ------ ------ ------ ------- -------
  4:146068652-146068652   T        intron_variant            *OTUD4*              13/20    rs12502109           0.31                 0.37                                     0.31                                     0.47   0.13   0.26   0.001   0.002
  20:43074372-43074372    C        downstream_gene_variant   *14kb 3' of HNF4A*   \-       rs1321826            0.16                 0.32                                     0.16                                     0.03   0.11   0.15   0.002   0.004
  20:43075161-43075161    A        downstream_gene_variant   *14kb 3' of HNF4A*   \-       rs7272694            0.16                 0.32                                     0.16                                     0.03   0.11   0.15   0.002   0.004
  20:43075280-43075280    C        downstream_gene_variant   *15kb 3' of HNF4A*   \-       rs7267639            0.16                 0.32                                     0.16                                     0.03   0.11   0.15   0.002   0.004
  5:142803548-142803548   G        intron_variant            *NR3C1*              1/8      rs72802815           0.25                 0.23                                     0.42                                     0.10   0.34   0.23   0.005   0.004
  16:16203559-16203559    T        intron_variant            *ABCC1*              21/29    rs35090860           0.21                 0.06                                     0.14                                     0.40   0.21   0.25   0.005   0.003
  16:16208172-16208172    T        intron_variant            *ABCC1*              22/29    rs45443999           0.20                 0.04                                     0.14                                     0.40   0.19   0.25   0.005   0.003
  16:16208173-16208173    C        intron_variant            *ABCC1*              22/29    rs45624535           0.20                 0.04                                     0.14                                     0.40   0.19   0.25   0.005   0.003
  4:146001613-146001613   T        intron_variant            *ANAPC10*            3/4      rs35098431           0.35                 0.51                                     0.32                                     0.47   0.13   0.26   0.005   0.004

-Tac troughs were adjusted in the extreme phenotype model for clinical variables and genotypes *CYP3A5\*3* and *CYP3A4\*22*.

Pvalb: Logistic regression with permutation applied to calculate p-value in the case-control trait test.

Pvalc: Linear regression applied to obtain p-values in the continuous trait test

###### Genetic Variants in the *CYB5R2* Gene Associated with Dose Normalized Tacrolimus Troughs in African American Kidney Transplant Recipients.

The table indicates the location of the variants in the *CYB5R2* gene, consequences, the codon changes, rs numbers and predicted protein effect from SIFT and PolyPhen2 analysis (with prediction scores), chromosome location of the variants based on GRCH37 assembly, the variant allele used to calculate the consequence, the consequence effect of the variant on the Ensembl transcripts, the Exon number out of the total number, Existing known variant rs numbers. Also shown are the allele frequencies from 1000 Genomes project as given by VEP software. AF = global, AFR = African population, AMR = American population, EUR = European population, EAS = East Asian population, SAS = South Asian population, AA = Allele Frequency from in African American population from Lung and Blood Institute-Exome Sequencing Project (NHLBI-ESP), EA = Allele Frequency in European American population from NHLBI-ESP.

  Location             Allele   Consequence        Exon   Existing_variation   SIFT                PolyPhen2                     Allele Frequencies                                                   
  -------------------- -------- ------------------ ------ -------------------- ------------------- ----------------------------- -------------------- ------- ------- ------- ------- ------- ------- -------
  11:7687146-7687146   A        missense_variant   9/9    rs67173996           deleterious(0.03)   Benign (0.019)                0.161                0.035   0.052   0.504   0.128   0.089   \-      \-
  11:7687715-7687715   C        missense_variant   8/9    rs12801394           deleterious(0.03)   Benign (0)                    \-                   0.853   0.679   0.817   0.763   0.766   0.852   0.771
  11:7689029-7689029   C        missense_variant   7/9    rs61733057           deleterious(0)      probably_damaging (0.947)     0.050                0.106   0.043   0.002   0.060   0.016   0.119   0.048
  11:7690873-7690873   T        missense_variant   4/9    rs61733056           Tolerated (0.08)    possibly\_ damaging (0.875)   0.075                0.213   0.035   0.014   0.004   0.053   0.192   0.003

[^1]: DeKAF Genomics Investigators
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